相关实验视频
Updated: Jan 8, 2026

04:49
Technique for Intranasal Administration of α-Synuclein Aggregates
Published on: November 8, 2024
962
对帕金森病的鼻内治疗的研究进展
Puyuan Wen1,2, Chao Ren1,3,4,5,6
1Department of Neurology, Yantai Yuhuangding Hospital Qingdao University Yantai Shandong China.
概括
鼻至脑药物输送为帕金森病 (PD) 治疗提供了一个有前途的替代方案,通过绕过血脑屏障来治疗帕金森病. 这种方法增强了药物输送到大脑,可能减少副作用,并改善PD患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药物输送系统 药物输送系统
背景情况:
- 帕金森病 (PD) 是一种影响生活质量的全球主要神经退行性疾病.
- 系统性药物输送到大脑面临重大挑战,包括血脑屏障 (BBB) 和第一通代谢.
- 不有效的全身传递需要更高的剂量,导致不良副作用和PD管理中的治疗效率降低.
研究的目的:
- 为帕金森病提供鼻入 (鼻至大脑,N2B) 治疗策略的全面概述.
- 评估N2B在PD临床前和临床研究中的进展和潜力.
- 讨论与神经系统疾病的N2B输送系统相关的生理障碍和局限性.
主要方法:
- 审查当前的临床前和临床研究对PD的鼻腔药物输送.
- 对影响N2B药物运输的生理方面的分析.
- 识别和讨论与N2B交付系统固有的挑战.
主要成果:
- 鼻到脑的注射绕过了BBB,使治疗药物能够直接输送到中枢神经系统.
- 这一途径增强了大脑的生物可用性,减少了酶降解,并最大限度地减少了与系统管理相比的系统性不良反应.
- 对于N2B输送的关键挑战包括粘膜清除,酶降解和药物外流机制.
结论:
- 鼻内注射提供了一种可行的策略,以克服帕金森病的全身传递限制.
- 需要进一步的研究和技术进步来应对N2B路径固有的挑战.
- 优化N2B输送具有显著的潜力,可以提高帕金森病治疗疗效和患者的治疗结果.
相关概念视频
Parkinson's Disease: Treatment
940
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
940
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

